Advertisement
U.S. Markets closed
S&P Futures
5,926.00 +6.00 (+0.10%) Dow Futures
43,575.00 +35.00 (+0.08%) Nasdaq Futures
20,659.50 +26.00 (+0.13%) Russell 2000 Futures
2,321.40 +3.70 (+0.16%) Crude Oil
69.16 0.00 (0.00%) Gold
2,628.70 +14.10 (+0.54%)
Adaptimmune Therapeutics plc (ADAP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 0.5866 |
| Open | 0.6000 |
| Bid | 0.5686 x 400 |
| Ask | 0.6277 x 300 |
| Day's Range | 0.5800 - 0.6380 |
| 52 Week Range | 0.4200 - 2.0500 |
| Volume | |
| Avg. Volume | 1,389,041 |
| Market Cap | 152.25M |
| Beta (5Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.43 |
Simply Wall St.Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.9m (up 459...
BioPharma DiveHalozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.